Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

NCT03169790 is registered in ClinicalTrials.gov with ImmunityBio, Inc. as lead sponsor.

NCT NCT03169790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03169790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
Lead sponsor
ImmunityBio, Inc.
Phase
Phase 1/2
Overall status
Withdrawn
Start date
December 31, 2017
Completion date
December 23, 2021
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non hodgkin lymphoma